aspirin has been researched along with terutroban in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (50.00) | 29.6817 |
| 2010's | 10 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cayatte, AJ; Cohen, RA; Du, Y; Lavielle, G; Oliver-Krasinski, J; Verbeuren, TJ | 1 |
| Adnot, S; Belhassen, L; Dubois-Rande, JL; Pelle, G | 1 |
| Berry, CL; Campbell, JH; Thomas, AC; Worth, NF | 1 |
| Bayat, H; Cohen, RA; Corda, S; Gu, J; Jiang, B; Lavielle, G; Maitland, KA; Nadler, JL; Verbeuren, TJ; Xu, S; Zuccollo, A | 1 |
| Verbeuren, TJ | 1 |
| Badimon, L; Casaní, L; Vilahur, G | 1 |
| Amarenco, P; Bousser, MG; Chamorro, A; Fisher, M; Ford, I; Fox, K; Hennerici, MG; Mattle, HP; Rothwell, PM | 1 |
| Butt, M; Lip, GY; Shantsila, E; Siddique, A | 1 |
| Amarenco, P; Bousser, MG; Chamorro, A; Fisher, M; Ford, I; Fox, K; Hennerici, M; Mattle, HP; Rothwell, PM | 1 |
| Bal Dit Sollier, C; Bergmann, JF; Bousser, MG; Crassard, I; Drouet, L; Simoneau, G | 1 |
| Ballerio, R; Banfi, C; Blanc-Guillemaud, V; Brioschi, M; Castiglioni, L; Gelosa, P; Gianella, A; Guerrini, U; Lerond, L; Nobili, E; Pignieri, A; Sironi, L; Tremoli, E | 1 |
| Bots, ML; Ford, I; Hennerici, MG; Laurent, S; Touboul, PJ | 1 |
| Bounameaux, H; Cairols, MA; Clement, DL; Coccheri, S; Fiessinger, JN; Fletcher, JP; Hoffmann, U; Turpie, AG | 1 |
| Diener, HC; Weber, R | 1 |
| Bracoud, L; Chabriat, H; Gass, A; Hennerici, M; Maeder, P; Michel, P | 2 |
| Lee, M; Ovbiagele, B | 1 |
| Amarenco, P; Bousser, MG; Chamorro, A; de Cordoüe, A; Fisher, M; Ford, I; Fox, KM; Fratacci, MD; Hennerici, MG; Mattle, HP; Rothwell, PM | 1 |
| De La Cruz, JP; González-Correa, JA; Guerrero, A; Jebrouni, N; López-Villodres, JA; Muñoz-Marín, J | 1 |
| Acciarresi, M; Caso, V; Paciaroni, M; Pezzella, FR; Santalucia, P | 1 |
4 review(s) available for aspirin and terutroban
| Article | Year |
|---|---|
[Terutroban and endothelial TP receptors in atherogenesis].
Topics: Animals; Apolipoproteins E; Aspirin; Atherosclerosis; Cell Adhesion; Cell Adhesion Molecules; Cholesterol; Clinical Trials as Topic; Dogs; Drug Evaluation, Preclinical; Endothelium, Vascular; Fibrinolytic Agents; Foam Cells; Guinea Pigs; Humans; Macrophages; Mice; Mice, Knockout; Models, Biological; Monocytes; Naphthalenes; Platelet Aggregation Inhibitors; Propionates; Receptors, Thromboxane A2, Prostaglandin H2; Swine; Thromboxane A2 | 2006 |
New antiplatelet drugs: beyond aspirin and clopidogrel.
Topics: Adenosine; Adenosine Monophosphate; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Drug Design; Humans; Imines; Lactones; Naphthalenes; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propionates; Purinergic P2 Receptor Antagonists; Pyridines; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention.
Topics: Aspirin; Blood-Brain Barrier; Cilostazol; Clopidogrel; Dipyridamole; Drug Interactions; Drug Therapy, Combination; Humans; Lactones; Naphthalenes; Platelet Aggregation Inhibitors; Propionates; Pyridines; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke; Succinates; Tetrazoles; Thrombosis; Ticlopidine | 2010 |
Antiplatelet treatment in primary and secondary stroke prevention in women.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female; Humans; Naphthalenes; Platelet Aggregation Inhibitors; Primary Prevention; Propionates; Salicylates; Secondary Prevention; Sex Factors; Stroke; Ticlopidine | 2012 |
8 trial(s) available for aspirin and terutroban
| Article | Year |
|---|---|
Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin.
Topics: Acetylcholine; Aged; Aspirin; Coronary Artery Disease; Cyclooxygenase Inhibitors; Double-Blind Method; Endothelium, Vascular; Forearm; Humans; Male; Middle Aged; Naphthalenes; Nitroprusside; Norepinephrine; Propionates; Receptors, Thromboxane; Regional Blood Flow; Tetrahydronaphthalenes; Thromboxane A2; Treatment Outcome; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2003 |
Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Double-Blind Method; Endpoint Determination; Female; Humans; International Cooperation; Ischemic Attack, Transient; Male; Middle Aged; Naphthalenes; Platelet Aggregation Inhibitors; Propionates; Receptors, Thromboxane; Stroke; Treatment Outcome | 2009 |
The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population.
Topics: Activities of Daily Living; Aged; Aspirin; Cognition; Diabetes Complications; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypertension; International Cooperation; Ischemic Attack, Transient; Male; Middle Aged; Naphthalenes; Platelet Aggregation Inhibitors; Propionates; Receptors, Thromboxane; Risk Factors; Secondary Prevention; Severity of Illness Index; Stroke | 2009 |
Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Intracranial Thrombosis; Male; Middle Aged; Naphthalenes; Platelet Aggregation; Platelet Aggregation Inhibitors; Propionates; Receptors, Thromboxane; Stroke; Ticlopidine | 2009 |
Rationale, design and population baseline characteristics of the PERFORM vascular project: an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke o
Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Carotid Arteries; Carotid Stenosis; Data Interpretation, Statistical; Double-Blind Method; Endpoint Determination; Epidemiologic Research Design; Female; Humans; Male; Middle Aged; Naphthalenes; Platelet Aggregation Inhibitors; Propionates; Quality Control; Reproducibility of Results; Sample Size; Stroke; Tunica Intima; Ultrasonography, Doppler, Duplex | 2010 |
Thromboxane Antagonism with terutroban in Peripheral Arterial Disease: the TAIPAD study.
Topics: Adenosine Diphosphate; Adult; Aged; Aspirin; Blood Pressure; Double-Blind Method; Female; Humans; Male; Middle Aged; Naphthalenes; Peripheral Arterial Disease; Placebos; Platelet Aggregation; Propionates; Thromboxanes; Time Factors | 2010 |
Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Naphthalenes; Platelet Aggregation Inhibitors; Propionates; Receptors, Thromboxane; Secondary Prevention; Stroke; Treatment Outcome | 2011 |
Results of the PERFORM magnetic resonance imaging study.
Topics: Aged; Aged, 80 and over; Aspirin; Brain; Brain Ischemia; Female; Fibrinolytic Agents; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Naphthalenes; Propionates; Secondary Prevention; Stroke | 2013 |
8 other study(ies) available for aspirin and terutroban
| Article | Year |
|---|---|
The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Aorta; Apolipoproteins E; Arteriosclerosis; Aspirin; Body Weight; Cell Adhesion; Cholesterol; Endothelium, Vascular; Female; Humans; Intercellular Adhesion Molecule-1; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Naphthalenes; Platelet Aggregation Inhibitors; Propionates; Receptors, Thromboxane; Tetrahydronaphthalenes; Thromboxane A2; Thromboxane B2; U937 Cells; Umbilical Veins; Vasoconstrictor Agents | 2000 |
S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits.
Topics: Animals; Aortic Diseases; Aspirin; Atherosclerosis; Catheterization; Diet, Atherogenic; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Female; Iliac Artery; Intercellular Adhesion Molecule-1; Macrophages; Male; Naphthalenes; Platelet Aggregation Inhibitors; Propionates; Rabbits; Receptors, Thromboxane; Recurrence; Rupture, Spontaneous; Tunica Intima; Tunica Media; Vasculitis | 2005 |
The thromboxane receptor antagonist S18886 attenuates renal oxidant stress and proteinuria in diabetic apolipoprotein E-deficient mice.
Topics: Animals; Apolipoproteins E; Arachidonate 12-Lipoxygenase; Aspirin; Diabetes Mellitus, Experimental; Female; Gene Deletion; Kidney Diseases; Mice; NADPH Oxidases; Naphthalenes; Nitric Oxide Synthase Type II; Oxidative Stress; Phosphoproteins; Propionates; Proteinuria; Receptors, Thromboxane | 2006 |
A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis.
Topics: Administration, Oral; Animals; Aorta; Aspirin; Bleeding Time; Blood Coagulation; Clopidogrel; Disease Models, Animal; Fibrin; Fibrinogen; Fibrinolytic Agents; Hemorrhage; Naphthalenes; Platelet Activation; Platelet Aggregation Inhibitors; Propionates; Prosthesis Design; Receptors, Thromboxane A2, Prostaglandin H2; Stainless Steel; Stents; Swine; Thrombosis; Ticlopidine; Time Factors | 2007 |
Terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, increases survival in stroke-prone rats by preventing systemic inflammation and endothelial dysfunction: comparison with aspirin and rosuvastatin.
Topics: Animals; Aspirin; Biomarkers; Blood Pressure; Brain; Endothelium, Vascular; Fluorobenzenes; Hypertension; Magnetic Resonance Imaging; Male; Naphthalenes; Propionates; Protective Agents; Pyrimidines; Rats; Rats, Inbred SHR; Receptors, Prostaglandin; Receptors, Thromboxane; Rosuvastatin Calcium; Stroke; Sulfonamides; Survival Analysis; Systemic Inflammatory Response Syndrome | 2010 |
Design, data management, and population baseline characteristics of the PERFORM magnetic resonance imaging project.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Image Interpretation, Computer-Assisted; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Naphthalenes; Propionates; Randomized Controlled Trials as Topic; Research Design; Secondary Prevention; Stroke | 2011 |
Vascular events after stroke: terutroban fails to PERFORM.
Topics: Aspirin; Early Termination of Clinical Trials; Humans; Naphthalenes; Platelet Aggregation Inhibitors; Propionates; Receptors, Thromboxane; Secondary Prevention; Stroke | 2011 |
Effects of terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, on retinal vascularity in diabetic rats.
Topics: Animals; Aspirin; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Epoprostenol; Lipid Peroxidation; Male; Naphthalenes; Platelet Aggregation; Propionates; Rats; Rats, Wistar; Receptors, Prostaglandin; Retinal Vessels; Streptozocin | 2012 |